These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Chronic splanchnic hemodynamic effects of low-dose transdermal nitroglycerin versus low-dose transdermal nitroglycerin plus spironolactone in patients with cirrhosis. Sugano S; Suzuki T; Nishio M; Makino H; Okajima T Dig Dis Sci; 1997 Mar; 42(3):529-35. PubMed ID: 9073134 [TBL] [Abstract][Full Text] [Related]
4. Hemodynamic study during transdermal application of nitroglycerin tape in patients with cirrhosis. Iwao T; Toyonaga A; Sumino M; Takagi K; Ohkubo K; Inoue R; Tanikawa K Hepatology; 1991 Jan; 13(1):124-8. PubMed ID: 1899080 [TBL] [Abstract][Full Text] [Related]
5. [Hemodynamic effects of the administration of terlipressin alone or combined with nitroglycerin in patients with cirrhosis]. Moreau R; Soubrane O; Hadengue A; Sogni P; Gaudin C; Kleber G; Lebrec D Gastroenterol Clin Biol; 1992; 16(8-9):680-6. PubMed ID: 1426824 [TBL] [Abstract][Full Text] [Related]
6. Vasopressin and vasopressin plus nitroglycerin for portal hypertension. Effects on systemic and splanchnic hemodynamics and coronary blood flow. Rector WG; Hossack KF J Hepatol; 1989 May; 8(3):308-15. PubMed ID: 2499616 [TBL] [Abstract][Full Text] [Related]
7. Effect of intraportal nitroglycerin on portosystemic hemodynamics in patients with cirrhosis: comparison with i.v. route. Iwao T; Toyonaga A; Sumino M; Takagi K; Ohkubo K; Inoue R; Tanikawa K J Clin Gastroenterol; 1991 Aug; 13(4):424-31. PubMed ID: 1918848 [TBL] [Abstract][Full Text] [Related]
8. Portohepatic pressures, hepatic function, and blood gases in the combination of nitroglycerin and vasopressin: search for additive effects in cirrhotic portal hypertension. Iwao T; Toyonaga A; Ikegami M; Sumino M; Oho K; Sakaki M; Nishizono M; Tanikawa K Am J Gastroenterol; 1992 Jun; 87(6):719-24. PubMed ID: 1590307 [TBL] [Abstract][Full Text] [Related]
9. Nitroglycerin improves the hemodynamic response to vasopressin in portal hypertension. Groszmann RJ; Kravetz D; Bosch J; Glickman M; Bruix J; Bredfeldt J; Conn HO; Rodes J; Storer EH Hepatology; 1982; 2(6):757-62. PubMed ID: 6815044 [TBL] [Abstract][Full Text] [Related]
10. Reduction of portal pressure by isosorbide-5-mononitrate in patients with cirrhosis. Effects on splanchnic and systemic hemodynamics and liver function. Navasa M; Chesta J; Bosch J; Rodés J Gastroenterology; 1989 Apr; 96(4):1110-8. PubMed ID: 2925055 [TBL] [Abstract][Full Text] [Related]
11. Long-term haemodynamic effects of isosorbide 5-mononitrate in patients with cirrhosis and portal hypertension. García-Pagán JC; Feu F; Navasa M; Bru C; Ruiz del Arbol L; Bosch J; Rodés J J Hepatol; 1990 Sep; 11(2):189-95. PubMed ID: 2123914 [TBL] [Abstract][Full Text] [Related]
12. Effects of isosorbide-5-mononitrate on variceal pressure and systemic and splanchnic haemodynamics in patients with cirrhosis. Escorsell A; Feu F; Bordas JM; García-Pagán JC; Luca A; Bosch J; Rodés J J Hepatol; 1996 Apr; 24(4):423-9. PubMed ID: 8738728 [TBL] [Abstract][Full Text] [Related]
13. Influence of nitroglycerin on portal pressure and gastric mucosal hemodynamics in patients with cirrhosis. Noguchi H; Toyonaga A; Tanikawa K J Gastroenterol; 1994 Apr; 29(2):180-8. PubMed ID: 8012507 [TBL] [Abstract][Full Text] [Related]
14. Low dose of nitroglycerin failed to improve splanchnic hemodynamics in patients with cirrhosis: evidence for an impaired cardiopulmonary baroreflex function. Moreau R; Roulot D; Braillon A; Gaudin C; Hadengue A; Bacq Y; Lebrec D Hepatology; 1989 Jul; 10(1):93-7. PubMed ID: 2500389 [TBL] [Abstract][Full Text] [Related]
15. Systemic and regional hemodynamic effects of isosorbide dinitrate in patients with liver cirrhosis and portal hypertension. Mols P; Hallemans R; Melot C; Lejeune P; Naeije R J Hepatol; 1989 May; 8(3):316-24. PubMed ID: 2732445 [TBL] [Abstract][Full Text] [Related]
16. Effects of somatostatin on hepatic and systemic hemodynamics in patients with cirrhosis of the liver: comparison with vasopressin. Bosch J; Kravetz D; Rodes J Gastroenterology; 1981 Mar; 80(3):518-25. PubMed ID: 6108897 [TBL] [Abstract][Full Text] [Related]
17. Effects of terlipressin on systemic, hepatic and renal hemodynamics in patients with cirrhosis. Narahara Y; Kanazawa H; Taki Y; Kimura Y; Atsukawa M; Katakura T; Kidokoro H; Harimoto H; Fukuda T; Matsushita Y; Nakatsuka K; Sakamoto C J Gastroenterol Hepatol; 2009 Nov; 24(11):1791-7. PubMed ID: 19686420 [TBL] [Abstract][Full Text] [Related]
18. Effects of molsidomine, a long acting venous dilator, on portal hypertension. A hemodynamic study in patients with cirrhosis. Ruiz del Arbol L; García-Pagán JC; Feu F; Pizcueta MP; Bosch J; Rodés J J Hepatol; 1991 Sep; 13(2):179-86. PubMed ID: 1744422 [TBL] [Abstract][Full Text] [Related]
19. Propranolol plus molsidomine vs propranolol alone in the treatment of portal hypertension in patients with cirrhosis. García-Pagán JC; Escorsell A; Feu F; Bandi JC; Moitinho E; Casado M; Bosch J; Rodés J J Hepatol; 1996 Apr; 24(4):430-5. PubMed ID: 8738729 [TBL] [Abstract][Full Text] [Related]
20. Hemodynamic effects of a combination of prazosin and terlipressin in patients with viral cirrhosis. Lee WC; Lin HC; Yang YY; Hou MC; Lee FY; Chang FY; Lee SD Am J Gastroenterol; 2001 Apr; 96(4):1210-6. PubMed ID: 11316172 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]